Related Experiment Video
Updated: Aug 13, 2026
Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Antibiotic prophylaxis in severe acute pancreatitis: the never-ending controversy
1Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.
Insights
Prophylactic antibiotics for severe acute pancreatitis are controversial. While some guidelines recommend them, recent trials show no benefit, suggesting targeted use only in pancreatic necrosis with specific antibiotics.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Critical Care Medicine
Background:
- Infections are a leading cause of death in severe acute pancreatitis.
- Historically, prophylactic antibiotics were recommended to prevent these infections.
- Recent evidence has challenged the routine use of prophylactic antibiotics.
Purpose of the Study:
- To review the current evidence on antibiotic prophylaxis in severe acute pancreatitis.
- To guide clinical decision-making regarding antibiotic use in this condition.
Main Methods:
- Review of prospective controlled trials, meta-analyses, and guidelines.
- Analysis of a key double-blind, placebo-controlled trial published in 2004.
- Evaluation of antibiotic penetration into pancreatic tissue.
Main Results:
- The efficacy of prophylactic antibiotics in severe acute pancreatitis is debated.
- Antibiotic prophylaxis showed no benefit in a major placebo-controlled trial.
- If used, antibiotics should target pancreatic necrosis and possess pancreatic penetration (e.g., imipenem, meropenem, cefepime).
- One-third of patients develop pancreatic necrosis infection despite prophylaxis.
- Without prophylaxis, 54-77% of patients require antibiotics for pancreatic or extrapancreatic infections.
Conclusions:
- The use of prophylactic antibiotics in severe acute pancreatitis remains controversial.
- Current evidence does not support routine prophylaxis; selective use in pancreatic necrosis is suggested.
- Vigilance for infection and appropriate antibiotic selection are crucial for patient management.
Abstract:
Infections are the most common late cause of morbidity and mortality in severe acute pancreatitis. Between 1993 and 2004, a number of prospective controlled trials, meta-analyses, and guidelines all concluded that antibiotics were indicated for the prophylaxis of infections in severe acute pancreatitis. However, in 2004, the first prospective, double-blind, placebo-controlled trial was published showing no effect of prophylactic antibiotics, thus rekindling the controversy surrounding this subject. For those physicians who choose to use prophylactic antibiotics, their use should be limited to patients with pancreatic necrosis, and the choice of antibiotic should be guided by the drug's proven ability to penetrate into the pancreas. Evidence supports imipenem, meropenem, or cefepime for this indication. One third of patients will develop infection of pancreatic necrosis despite the use of prophylactic antibiotics. Vigilance must be maintained for evidence of recurrence of markers of inflammation or persistence beyond the first week, which would suggest the need for fine-needle aspiration and culture to detect infection. Physicians who choose not to use prophylactic antibiotics for pancreatic necrosis should be aware that they will need to initiate antibiotics in 54% to 77% of patients for either infection of pancreatic necrosis or extrapancreatic infections.
Related Concept Videos
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:25Acute Pancreatitis I: Introduction
01:21Acute Pancreatitis II: Pathophysiology
01:25Chronic Pancreatitis I: Introduction